News Image

Hoth Therapeutics Expands HT-001 Development with Patent Filings Targeting Drug-Induced Hypersensitivity, Radiotherapy-Induced Rash, and MENIN Inhibitor-Associated Skin Toxicities

Provided By PR Newswire

Last update: Sep 24, 2025

MENIN inhibitors are a promising class of targeted oncology drugs in development for acute leukemias and certain solid tumors, but their use is often limited by severe dermatological side effects. HT-001 aims to address these toxicities, helping patients remain on therapy and realize the full benefit of treatment.

Read more at prnewswire.com

HOTH THERAPEUTICS INC

NASDAQ:HOTH (10/1/2025, 11:42:19 AM)

1.63

+0.01 (+0.62%)



Find more stocks in the Stock Screener

Follow ChartMill for more